{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-295622","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2026-07-06T12:15:35+00:00","discovered_at":"2026-07-06T12:20:02.347729+00:00","generated_at":"2026-07-06T12:20:06.738018+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Corbus appoints Leonardo Viana Nicacio as CMO; base salary $545K, equity $2.1M","bullets":["Dr. Nicacio appointed CMO effective Aug 3, 2026; base salary $545K, target bonus up to 40%, equity inducement awards of $2.1M.","He brings ADC and HPV-driven oncology experience, previously CMO at Protara, VP at Seagen (TIVDAK), and roles at AstraZeneca, Flatiron Health.","Corbus expects to initiate TEMPO-1 registrational study of CRB-701 in 2L OPSCC summer 2026; topline CANYON-1 obesity study data late summer 2026.","Employment agreement for 2 years, includes non-compete (6 months post) and non-solicitation (12 months post), severance provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-295622","json":"https://secwatch.observer/filing/0001193125-26-295622.json","markdown":"https://secwatch.observer/filing/0001193125-26-295622.md","text":"https://secwatch.observer/filing/0001193125-26-295622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526295622/0001193125-26-295622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526295622/crbp-20260702.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-06T12:20:06.738018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}